Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.

Internal medicine journal - 1 Dec 2014

Stone E, Allen H A, Saghaie T, Abbott A, Daniel R, Mead R S, Kohonen-Corish M, Plit M, Morgan L

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutation positivity in primary non-small-cell lung cancer (NSCLC) may confer increased sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy with improved progression-free survival over EGFR wild-type tumours. Some mutation subtypes may not confer such TKI sensitivity. The incidence of rare and compound subtypes in the Australian lung cancer population is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Australia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to Disease Progression

Share to ErbB Receptors

Share to Incidence

Share to Lung Neoplasms

Source

Identifiers

PMID: 25228365
DOI: 10.1111/imj.12587

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.PMID 25228365Read ↗

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.Semantic proximity Read ↗

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.Semantic proximity Read ↗

Prevalence of the EGFR T790M and other resistance mutations in the Australian population and histopathological correlation in a small subset of cases.Semantic proximity Read ↗

Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case reportSemantic proximity Read ↗

The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.Semantic proximity Read ↗

Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.Semantic proximity Read ↗

Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Māori and Pacifica in New Zealand.Semantic proximity Read ↗

De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.Semantic proximity Read ↗

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.Semantic proximity Read ↗

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.